We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+32.58%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.99B
AUM Growth
+$476M
Cap. Flow
+$118M
Cap. Flow %
5.96%
Top 10 Hldgs %
48.1%
Holding
113
New
18
Increased
27
Reduced
34
Closed
25

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$62.7M
2
ELV icon
Elevance Health
ELV
+$59M
3
TGTX icon
TG Therapeutics
TGTX
+$52.7M
4
TWST icon
Twist Bioscience
TWST
+$45.8M
5
NVCR icon
NovoCure
NVCR
+$36.6M

Top Sells

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$73.4M
2
STAA icon
STAAR Surgical
STAA
+$59.2M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$37.3M
4
GRFS
Grifois
GRFS
+$32.5M
5
URGN icon
UroGen Pharma
URGN
+$27M

Sector Composition

Rank Sector Weight
1 Healthcare 94.2%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
51
DELISTED
Arcellx
ACLX
$8.21M 0.41%
100,000
-23,031
-19% -$1.66M
NUVL
52
DELISTED
Nuvalent
NUVL
$7.61M 0.38%
88,000
-37,000
-30% -$2.93M
ALNY icon
53
Alnylam Pharmaceuticals
ALNY
$28.8B
$6.95M 0.35%
15,250
-91,500
-86% -$37.3M
JBIO
54
Jade Biosciences
JBIO
$1.39B
$6.88M 0.35%
796,744
– –
LBRX
55
LB Pharmaceuticals
LBRX
$1.39B
$6.32M 0.32%
+400,000
New +$6.35M
OLMA icon
56
Olema Pharmaceuticals
OLMA
$1.05B
$6.07M 0.31%
+619,874
New +$3.72M
KNSA icon
57
Kiniksa Pharmaceuticals
KNSA
$6.03B
$5.82M 0.29%
150,000
-104,689
-41% -$3.4M
ESTA icon
58
Establishment Labs
ESTA
$2.27B
$5.72M 0.29%
139,512
-72,388
-34% -$2.96M
MBX
59
MBX Biosciences
MBX
$3.21B
$4.81M 0.24%
+275,000
New +$3.68M
ERAS icon
60
Erasca
ERAS
$6.4B
$4.71M 0.24%
2,162,162
– –
ETON icon
61
Eton Pharmaceutcials
ETON
$1.27B
$4.35M 0.22%
200,000
-85,000
-30% -$1.41M
CBLL
62
CeriBell Inc
CBLL
$691M
$4.14M 0.21%
360,000
+310,000
+620% +$4.18M
HROW icon
63
Harrow
HROW
$1.53B
$4.12M 0.21%
+85,498
New +$3.22M
GUTS icon
64
Fractyl Health
GUTS
$111M
$3.98M 0.2%
+2,500,000
New +$3.24M
JSPR icon
65
Jasper Therapeutics
JSPR
$21.7M
$3.56M 0.18%
1,494,420
– –
NSPR icon
66
InspireMD
NSPR
$32.4M
$3.54M 0.18%
1,470,934
-415,273
-22% -$1.01M
AKRO
67
DELISTED
Akero Therapeutics
AKRO
$3.37M 0.17%
71,000
-1,000
-1% -$48.4K
IDYA icon
68
IDEAYA Biosciences
IDYA
$3.54B
$2.72M 0.14%
100,000
-150,000
-60% -$3.63M
TNGX icon
69
Tango Therapeutics
TNGX
$4.65B
$2.52M 0.13%
300,000
-430,000
-59% -$2.91M
CBIO
70
Crescent Biopharma
CBIO
$627M
$2.38M 0.12%
200,000
-200,000
-50% -$2.65M
RAPP
71
Rapport Therapeutics
RAPP
$2.23B
$2.38M 0.12%
+80,000
New +$1.43M
KIDS icon
72
OrthoPediatrics
KIDS
$592M
$2.37M 0.12%
128,000
+83,000
+184% +$1.71M
IOVA icon
73
Iovance Biotherapeutics
IOVA
$2.9B
$2.12M 0.11%
976,707
-2,285,000
-70% -$5.4M
CALC icon
74
CalciMedica
CALC
$11.3M
$2.1M 0.11%
683,904
-100,000
-13% -$288K
VTGN icon
75
VistaGen Therapeutics
VTGN
$13.2M
$1.95M 0.1%
+550,000
New +$1.64M
1 2
3
4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Soleus Capital Management held 113 positions worth $1.99B, up 32% from $1.51B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Soleus Capital Management deployed $118M of net new capital in Q3 2025, opening 18 new positions and adding to 27 existing holdings. Its largest new stake was Amicus Therapeutics: 4,690,000 shares worth $37M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Celcuity, an estimated $73.4M trimmed.

  • Soleus Capital Management's largest Q3 2025 buy was Amicus Therapeutics: 4,690,000 shares worth $37M.
  • Soleus Capital Management added most to Inspire Medical Systems in Q3 2025, an estimated $62.7M increase.
  • Soleus Capital Management's biggest Q3 2025 reduction was Celcuity, cutting an estimated $73.4M.
  • Soleus Capital Management fully exited UnitedHealth in Q3 2025, selling an estimated $26.9M.
  • Soleus Capital Management's ten largest holdings make up 48% of its $1.99B portfolio in Q3 2025.
  • Soleus Capital Management opened 18 new positions and closed 25 in Q3 2025.
  • Soleus Capital Management's portfolio value rose 32% quarter-over-quarter to $1.99B.

Based on Soleus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.